<?xml version='1.0' encoding='utf-8'?>
<document id="26233803"><sentence text="Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction."><entity charOffset="50-59" id="DDI-PubMed.26233803.s1.e0" text="docetaxel" /><entity charOffset="64-73" id="DDI-PubMed.26233803.s1.e1" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.26233803.s1.e0" e2="DDI-PubMed.26233803.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26233803.s1.e0" e2="DDI-PubMed.26233803.s1.e1" /></sentence><sentence text="Docetaxel and gefitinib play key roles in the treatment of non-small-cell lung cancer (NSCLC), and their combination could be of interest"><entity charOffset="0-9" id="DDI-PubMed.26233803.s2.e0" text="Docetaxel" /><entity charOffset="14-23" id="DDI-PubMed.26233803.s2.e1" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.26233803.s2.e0" e2="DDI-PubMed.26233803.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26233803.s2.e0" e2="DDI-PubMed.26233803.s2.e1" /></sentence><sentence text=" Both drugs are mainly metabolized by CYP3A4, and drug-drug interactions are a major concern" /><sentence text=" This phase I dose-finding study was designed to assess the tolerability and drug-drug interactions in this combination using full pharmacokinetic (PK) samplings" /><sentence text="" /><sentence text="Docetaxel was intravenously administered on days 1 and 22 at a dose of 45 or 60 mg/m(2)"><entity charOffset="0-9" id="DDI-PubMed.26233803.s6.e0" text="Docetaxel" /></sentence><sentence text=" Gefitinib (250 mg/day) was orally administrated starting on day 2"><entity charOffset="1-10" id="DDI-PubMed.26233803.s7.e0" text="Gefitinib" /></sentence><sentence text=" Ten PK samplings of docetaxel were performed on days 1 and 22"><entity charOffset="21-30" id="DDI-PubMed.26233803.s8.e0" text="docetaxel" /></sentence><sentence text=" Seven PK samplings of gefitinib were performed on day 18 Â± 3 and on day 22"><entity charOffset="23-32" id="DDI-PubMed.26233803.s9.e0" text="gefitinib" /></sentence><sentence text="" /><sentence text="Twelve patients with advanced or metastatic NSCLC were enrolled without considering EGFR mutation status" /><sentence text=" The major toxicity was neutropenia" /><sentence text=" Two patients withdrew from this study due to dose-limiting toxicities; however, the toxicity profiles in this combination were generally acceptable" /><sentence text=" The docetaxel AUC0-24 and C max did not differ whether administered alone or with gefitinib, and the geometric mean ratios (GMRs) of AUC0-24 and C max (co-administrated/administrated alone) were 0"><entity charOffset="5-14" id="DDI-PubMed.26233803.s14.e0" text="docetaxel" /><entity charOffset="83-92" id="DDI-PubMed.26233803.s14.e1" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.26233803.s14.e0" e2="DDI-PubMed.26233803.s14.e0" /><pair ddi="false" e1="DDI-PubMed.26233803.s14.e0" e2="DDI-PubMed.26233803.s14.e1" /></sentence><sentence text="95 (90 % CI 0" /><sentence text="85-1" /><sentence text="06) and 0" /><sentence text="95 (90 % CI 0" /><sentence text="85-1" /><sentence text="05), respectively" /><sentence text=" Furthermore, the GMRs of the steady state gefitinib AUC0-24 and C max were 0" /><sentence text="93 (90 % CI 0" /><sentence text="84-1" /><sentence text="03) and 0" /><sentence text="98 (90 % CI 0" /><sentence text="88-1" /><sentence text="09), respectively" /><sentence text="" /><sentence text="The tolerability of 60 mg/m(2) docetaxel with 250 mg/day gefitinib was confirmed, and we observed no drug-drug interaction in this combination"><entity charOffset="31-40" id="DDI-PubMed.26233803.s29.e0" text="docetaxel" /><entity charOffset="57-66" id="DDI-PubMed.26233803.s29.e1" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.26233803.s29.e0" e2="DDI-PubMed.26233803.s29.e0" /><pair ddi="false" e1="DDI-PubMed.26233803.s29.e0" e2="DDI-PubMed.26233803.s29.e1" /></sentence><sentence text="" /></document>